tbuckley/cabot-search huggingface dataset:
Tailored treatment strategy for locally advanced rectal carcinoma: Five-year results of the French phase II, randomized, multicenter GRECCAR4 trial.
Authors: Philippe Rouanet
Journal: Journal of Clinical Oncology (2020)

4014 Background: Preoperative radiochemotherapy and total mesorectal excision are the standard-of-care for locally-advanced rectal carcinoma, but some patients are over- or undertreated. Our phase II study assessed the feasibility of tailored radiochemotherapy, based on tumor response to induction high-dose chemotherapy (FOLFIRINOX). Methods: We enrolled 206 patients; good responders after chemotherapy (≥75% tumor volume reduction) were randomly assigned to immediate surgery (arm A) or standard radiochemotherapy (Cap 50: 50 Gy and oral capecitabine daily) plus surgery (arm B). Poor responders were randomly assigned to Cap 50 (arm C) or intensive radiochemotherapy (Cap 60 (60 Gy irradiation), arm D) before surgery. Results: After induction treatment, 194 patients were classified as good (n=30, 15%) or poor (n=164, 85%) responders, and included in arms A and B (16 and 14 patients) or C and D (113 and 51 patients). The primary objective was obtained: (90% CI) R0 resection rates in the four arms respectively were 100% (74–100), 100% (85–100), 83% (72–91), and 88% (77–95). At 5 years: overall survival 90% (CI: 47.3-98.5), 93.3% (CI: 61.3-99.0), 84.3% (CI: 71.0-91.8), 86.1% (CI: 71.6-93.5); disease-free survival 80% (CI: 40.9-94.6), 89.5% (CI: 64.1-97.3), 72.9% (CI: 58.5-82.9), 72.8% (CI: 57.7-83.2); local recurrence 0, 0, 2.1% (CI: 0.3-13.9), 9.3% (CI: 3.6-23.0); metastasis 20% (CI: 5.4-59.1), 10.5% (CI: 2.7-35.9), 18% (CI: 31.8-94.6), 18.8% (CI: 10.2-33.0). Late morbidity and quality of life evaluations showed no significant difference between arms. Conclusions: Tailoring preoperative radiochemotherapy based on induction treatment response is safe and promising. Early tumoral response to induction chemotherapy can discriminate tumor prognosis. Clinical trial information: NCT01333709 .
上海某社区居民感冒抗生素使用状况及其影响因素分析
Authors: 解军, 周鑫
Journal: BMJ (2004)

2002年6月在上海某社区对300名社区居民进行感冒与抗生素使用情况调查.发现因感冒使用抗生素者152人,其中抗生素来源于医院占56.6%,使用抗生素原因中医生的决定占52.2%,而抗生素使用越多医疗费用越高(P=0.001)
以鼻尖痛为表现的急性心肌梗死一例
Authors: 宋凯
Journal: BMJ (2009)

患者男,59岁,因发作性鼻尖部烧灼样疼痛15 d,加重伴唇痛,恶心10 h入院.15 d前于晨练时出现鼻尖部刺痛,晨练结束后20 min鼻尖部刺痛自行缓解.第2天,于晨练时再次出现鼻尖部刺痛,就诊于当地医院耳鼻喉科,诊为三叉神经炎,治疗10 d无效.10 h前鼻尖部疼痛加重,为烧灼样剧痛,伴大汗,烦躁,持续不缓解,急诊人我院.患糖尿病10年,无高血压病史.查体:体温37.1℃,脉搏96次/min,呼吸24次/min,血压160/90 mm Hg(21/12 kPa),颜面苍白,大汗,神志清楚,痛苦表情,口唇轻度紫绀,颈软无抵抗。
Comprehensive genomic landscape in Chinese patients with urothelial carcinoma.
Authors: Haige Chen, Ruiyun Zhang, Shiqing Chen, Yuezong Bai
Journal: Journal of Clinical Oncology (2020)

e17009 Background: Recent therapeutic advances, such as immunotherapy and FGFR-targeted therapy, have greatly improved the prognosis of patients with urothelial carcinoma (UC). Revealing comprehensive genomic features could evolve our understanding of UC, however the genomic landscape in Chinese UC has not been fully elucidated. In the present study, we investigated the molecular features of Chinese UC patients. Methods: Genomic profiling was performed through next generation sequencing (NGS) from Chinese patients with UC between January, 2017 and November, 2019 in a College of American Pathologists-certified and Clinical Laboratory Improvement Amendments-accredited lab. DNA was extracted from formalin fixed paraffin-embedded (FFPE) tumor specimens or fresh tumor tissue. IHC staining for PD-L1 expression was performed using PD-L1 IHC 22C3 pharmDx assay or Ventana PD-L1 SP263 assay. Data analyses were performed using SPSS and R 3.6.1. Results: A total of 298 Chinese UC patients who have undergone NGS were included in this study, including 210 (70.5%) male and 88 (29.5%) female patients. The median age was 66 (range, 19-91) years old. The most common somatic alterations were detected in TP53 (57.0%), KMT2D (42.6%), TERT (28.2%), KDM6A (26.5%) and PIK3CA (18.8%). Of the 243 patients who were evaluated for PD-L1 expression, 78 (32.1%) had a PD-L1 Tumor Proportion Score (TPS) of 1% or greater, and 18 (7.4%) had a PD-L1 TPS of 50% or greater. The median TMB value was 9.7 muts/Mb (range: 0-175.0). 138 (46.3%) patients harbored alterations in DNA damage repair (DDR) genes, including pathogenic or likely pathogenic mutations (MUT) and variants of unknown significance (VOUS). The most common somatic alterations in DDR genes were detected in ATM (9.4%), BRCA2 (9.4%), BRIP1 (5.0%), ATR (4.7%) and BRCA1 (4.7%). Significant differences of TMB were observed among DDR-MUT group, DDR-VOUS group and DDR-WT group (mTMB = 16.1, 14.0 and 7.3 muts/Mb, respectively, P &lt; 0.001). Seven (2.4%) patients were identified as MSI-H, including five patients in DDR-MUT group (12.8%) and two patients in DDR-VOUS group (2.0%). Conclusions: This is the first large-scale comprehensive genomic analysis for Chinese patients with UC. These results provide a better understanding of molecular features in Chinese UC patients which may lead to an improvement in the personalized treatment for these patients.
Enhancing awareness and management of obstructive sleep apnea in primary care
Authors: Yi Xiao
Journal: BMJ (2019)

阻塞性睡眠呼吸暂停（OSA）发病率较高，与一些常见慢性病的发生相关，如心血管疾病、肿瘤、慢性阻塞性肺疾病、脑卒中、糖尿病等，成为全球性的公共健康问题。文章概述了OSA的流行病学、病理生理机制、与慢性病的相关性、医疗费用及诊断方法等，旨在提高基层医务人员对OSA的重视，对其进行有效的识别、诊疗与管理治疗和管理。《成人阻塞性睡眠呼吸暂停基层诊疗指南（2018年）》的出台，将系统地指导基层医务人员进行OSA管理，从而改善相关慢性病的病情，提高生命质量。
A case of colon cancer with synchronous primary hepatocellular carcinoma
Authors: Hairui Wu
Journal: BMJ (2017)

报道1例术前诊断为大肠癌伴同时性肝转移，行同时性手术治疗，术后病理诊断为大肠癌并发原发性肝细胞肝癌，通过此例强调对于肝脏占位的原发性肿瘤及转移性肿瘤术前鉴别的重要性，并提高及加深临床医师对于同时性多原发癌的认识。
T-cell receptor gene rearrangement clonality, flow cytometry status, and associated outcomes in early-stage CTCL.
Authors: Jennifer Aline Marks, Jeffrey M. Switchenko, Pamela Blair Allen, Mary Jo Lechowicz
Journal: Journal of Clinical Oncology (2020)

e20087 Background: Cutaneous T-Cell Lymphoma (CTCL) is a monoclonal lymphoproliferative disease. Studies hypothesize T-cell receptor gene (TCR) rearrangement and flow cytometry as means of predicting those at risk of aggressive disease. We aimed to assess outcomes in early-stage disease by TCR clonality and flow cytometry in peripheral blood. Methods: We performed a retrospective analysis of 328 pts with early-stage (1-2A) CTCL using our internal CTCL database with protocol approved by our institutional review board (IRB00045798). Early-stage CTCL pts included were those with TCR clonality and/or flow cytometry in the peripheral blood obtained within 6 months of diagnosis and/or at initial check. Overall survival (OS) and time to next treatment (TTNT) were examined. Missing data or OS/ TTNT values larger than 25 years were excluded. Univariate/multivariate models and Kaplan-Meier analyses were run for both OS and TTNT. Results: In the cohort (n = 328) the median age was 53.2 years (8.6-87.5), with equal sex predominance, and distribution among stages. 261 pts had TCR clonality assessed. 78.5% (n = 205) were non-clonal and 21.5% (n = 56) were clonal. 284 pts had flow assessed (n = 44/328 with missing data). 89.8% (255/284) were flow (-), initially. Of those without clonality, 95.29% (n = 182 p &lt; 0.001) were flow (-). 76% (38/56 p &lt; 0.001) with TCR clonality were flow (-). TCR clonality in the blood was not associated with a survival nor TTNT by univariate or multivariate analyses. Age at diagnosis was significant contributing to OS and TTNT in multivariate analyses (HR 1.04,CI 1.01-1.06,p &lt; 0.01;HR 1.01, CI 1.00-1.02,p = 0.033, respectively). Flow cytometry status was not associated with TTNT. Flow cytometry in the blood was associated with survival but was limited to stage 2A pts (n = 98, p = 0.0171). Median survival of those with flow negative results was 20.8 yrs (CI 11.8,NA, p = 0.0171) with a 5-year survival of 95.8%(CI 87.4%-98.6%) compared to those with positive results of 12 yrs (CI 1.3, NA), p = 0.0171) with a 5-yr survival of 80.8%(CI 42.3%-94.9%). Conclusions: We found no difference in OS or TTNT by TCR status in blood for stage 1-2A disease. Flow cytometry status and OS differed in stage 2A pts. Significance of TCR clonality or flow cytometry in early-stage disease remains unclear. Findings raise questions of needing to risk-stratify in early-stage disease by TCR gene rearrangement or flow cytometry. Those with stage 2A disease, flow cytometry status may confer some benefit. Larger cohorts needed to further investigate these findings.
Patients over 65 with early breast cancer and preference for intraoperative radiation despite no survival benefit.
Authors: Annie Tang, Jason F. Kelly, Elizabeth Cureton, Veronica Shim
Journal: Journal of Clinical Oncology (2020)

e12612 Background: Patients over 65 years of age with early-stage hormone receptor (HR)-positive breast cancer have many radiation treatment options based on the PRIME II and CALGB 9343. Our study aims to evaluate treatment preference of patients over 65 years of age when intraoperative radiation therapy (IORT) is offered. Methods: A retrospective chart review was conducted among patients over 65 years old diagnosed with early-stage HR-positive breast cancer during 2016-2019 in a single breast program in a large integrated healthcare system. At our institution, every breast cancer patient is reviewed at a weekly multi-disciplinary breast conference for IORT eligibility and tracked prospectively. All patients in this study met with breast surgeons and radiation oncologists prior to their locoregional treatment decisions. We identified patients who were offered IORT as an option. The tumor board discussion, treatment team recommendation, and the final patient decision for radiation were obtained from the chart review. Demographics including age, race, hormone therapy, and co-morbidities (Charlson Comorbidity Index) were collected. Logistic regression analysis was used to evaluate if any factors were associated with patients’ radiation treatment choice. Results: Among 225 patients who were over 65 with early endocrine responsive breast cancer, 63 patients met the IORT guideline (28%). Their ages ranged from 65-86 with a mean of 70.4 years. 74.6% of patients chose IORT compared with 14.3% who opted for whole breast radiation. Only 4.8% of patients chose to omit radiation after breast-conserving surgery, and 6.3% chose mastectomy. Patients who chose IORT was also more likely to take endocrine treatment (OR 4.76 CI 1.42-16.0, p = 0.01). Age, race, and co-morbidities were not associated with preference for IORT (OR 0.95 p = 0.34, OR 1.09 p 0.92, and OR 1.15 p = 0.53, respectively). Conclusions: Early-stage breast cancer patients over age 65 with HR-positive disease overwhelmingly desired radiation treatment even after being counseled that it does not confer an overall survival benefit. IORT was strongly preferred over whole breast radiation. This finding indicates that these women choose to maximize their local cancer control, regardless of its impact on overall survival, and prefer the convenience of single fraction, integrated radiation delivery. Further studies need to be completed on patient reported outcomes in this study population.
Neoadjuvant itraconazole (I) in patients (pts) with resectable basal cell carcinoma (BCC): A phase II multistage study.
Authors: Rodrigo Perez Pereira, Sergio Jobim Azevedo, Juliano Cé Coelho, Taiane Francieli Rebelatto, Gabriela Lusa Viapiana, Facundo Zaffaroni, Leonardo Augusto Schreiner, Gustavo Cartaxo de Lima Gössling, Luis Rivero, Renato Marchiori Bakos
Journal: Journal of Clinical Oncology (2020)

e22081 Background: Targeting the hedgehog (HH) protein family pathway has consistently shown activity in locally advanced and metastatic BCC. Itraconazole is an affordable agent with known toxicity profile that demonstrates in vitro HH signaling inhibition, suggesting a possible role in BCC treatment. Initial results of a phase 2 study designed to investigate efficacy of Itraconazole as neoadjuvant treatment in patients with resectable BCC are reported. Methods: Eligible pts had biopsy-proven resectable BCC, ECOG PS 0-3, adequate organ function and measurable disease. Dosing of I consisted of 200mg twice daily for 60 days followed by surgery. Simon two-stage design was used to test a null rate of 5% vs. 20% (power = 0.80; α = 0.05, unilateral). If ≥1 of 13 pts in stage 1 have objective response (OR) according to RECIST 1.1 criteria, 14 more pts will be enrolled. If ≥4 of 27 pts have OR, the treatment is worthy of further study. Secondary endpoints include safety and change in Ki-67 and Gli1. Results: Thirteen pts with 14 measurable lesions enrolled from Jan/2018 to Feb/2019; 1 pt was not evaluable, but was included in safety analysis. Demographics and outcomes are summarized in Table. After 60 days of treatment, all patients had R0 resection as primary planned and 1 (8.3%) PR was observed. There were no progressions during the study. OR rate was 8.3%. No grade 3 AE or SAE were reported. 6 pts had grade 1 or 2 AEs at least possibly related to I including depression, headache, GPT elevation, diarrhea, abdominal pain and bilirubin elevation. Conclusions: Itraconazole showed initial anti-tumor activity in pts with resectable BCC, no safety concerns were observed. Study will proceed to Simon’s second stage. Clinical Trial Information: NCT03972748 , 47011715.0.0000.5327 . [Table: see text]
Real-world outcomes of pembrolizumab in peritoneal mesothelioma.
Authors: Melina Elpi Marmarelis, Xiao Wang, Leonid Roshkovan, Suzanne Walker, Sally McNulty, Christine Agnes Ciunci, John Muira, Sharyn I. Katz, Keith A. Cengel, Giorgos Karakousis, Corey J. Langer
Journal: Journal of Clinical Oncology (2020)

e21094 Background: Clinical trials evaluating pembrolizumab (P) in malignant mesothelioma (MM) have included small numbers of peritoneal MM (MPM) patients (pts), but the efficacy of P in the MPM subpopulation remains unclear. We evaluated the efficacy of P in a cohort of MPM pts treated at our institution. Methods: This retrospective cohort study identified MPM pts via ICD9/10 codes seen at our institution between 1/1/2009 and 9/1/2019. Pts were included if they received P as treatment for MPM. Median progression free survival (PFS) and median overall survival (mOS) were estimated from Kaplan-Meier curves. PFS was defined as the start of P until radiologic or clinical progression. Best overall response rate (BOR) and disease control rate (DCR) were determined retrospectively using RECIST 1.1 criteria. Results: We identified 13 non-papillary MPM pts who received P. All pts had received prior chemotherapy (12 platinum/pemetrexed, 1 pemetrexed). Median age at diagnosis was 65.6 years; 77% were white; 46% never smokers; 62% with known asbestos exposure; 70% epithelioid/15% biphasic/ 7.7% sarcomatoid/ 7.7% desmoplastic. BOR to P was 18% (Partial response (PR): 2, Progressive disease (PD): 2, Stable disease (SD): 7, Lost to follow up: 2). DCR was 81% and mPFS 5.7mo. From the start of P mOS was 20.9 mo. Only 3 pts had known PDL1 positivity (1%, 2%, 80%), 4 were negative, 6 untested. Median PFS was not statistically different between PDL1 positive and negative pts (mPFS 5.1mo vs. 5.7 mo, log rank p = 0.73, respectively). Three pts experienced a PFS of &gt; 2 years (PDL1/BOR/% tumor change: Unknown/SD/19%, Negative/SD/-21%, 80%/PR/-70%). The patient with PDL1 80%, biphasic histology and a PR experienced skin toxicity requiring a treatment break. Outcomes for epithelioid histology vs non-epithelioid after P did not differ statistically (mPFS 5 mo vs 39 mo, log rank p = 0.14; mOS 17.5 mo vs NA, log rank p = 0.31). Conclusions: In a real world setting, P has clinically meaningful activity in a PDL1 unselected cohort of MPM pts and should be considered a treatment option for this subpopulation of MM. We did not detect a difference in outcomes based on PDL1 level or histology.
Implementation and effectiveness of "Three-in-One" family doctor contract service model in Xiamen
Authors: Guobao Tang, Jie Jiang
Journal: BMJ (2018)

A Three-in-One model of family doctor contract service was proposed in July 2014 and then implemented in Xiamen. In this model the health service was provided to contracted residents by a team consisted of specialists from tertiary hospitals, general practitioners and health manager in community health service centers. After the implementation of the model, the proportion of visiting in primary care institutions among the residents surpassed that in hospital visiting, appearing a inflection point. The satisfaction of the residents increased significantly, meanwhile the income of primary care medical staff increased substantially and the position of primary care seemed to be more attractive. The Three-in-One service model of Xiamen may provide valuable experiences for implementation of family doctor contract service and hierarchichal medical service system in other areas of China.


Key words: 
General practitioners; Family doctor contract
Prevalence of conjunctivitis symptoms and associated factors among residents in Beijing, China
Authors: Yang Zheng, Shuangsheng Wu, Chunna Ma, Peng Yang
Journal: BMJ (2014)

A multi-stage stratified sampling method and a self-designed questionnaire were used to evaluate the prevalence of conjunctivitis symptoms and associated factors among the Beijing residents. In total, 12 890 residents aged over 18 years were recruited from 6 districts. The reported prevalence of conjunctivitis symptom at the last years was 1.60%. Self-reported health condition and personal health behaviors were risk factors associated with conjunctivitis among adult Beijing residents. No significant difference existed between different districts, age groups, educational levels, gender and races. Conjunctivitis symptom among Beijing residents was related with health condition and health behaviors. More measures should be taken to cultivate the health model of behaviors.


Key words: 
Conjunctivitis; Influence factor
Study on prognostic factors of patients with upper urinary tract urothelial carcinoma treated with Gemcitabine and Cisplatin
Authors: Jing Xiao, Jimeng Ruan, Miaomiao Wang, Xiangyu Wang, Tiandong Han, Caixiang Zhang, Meiyuan Chen, Xin Tong, Yichen Zhu
Journal: International Journal of Surgery (2018)
Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC.
Authors: Michael Rahman Shafique, Terrence Lee Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Electa Pastore, Crystal L. Mallow, Ernest Smith, Andreas Schröder, Kevin M. Chin, Joseph Thaddeus Beck, Megan Ann Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Rachel E. Sanborn, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron Scott Mansfield, Jonathan Wade Goldman, Maurice Zauderer
Journal: Journal of Clinical Oncology (2020)

3011 Background: Antibody blockade of semaphorin 4D (SEMA4D, CD100) promotes tumoral dendritic cell and CD8+ T cell infiltration and reduces function and recruitment of immunosuppressive myeloid cells. Importantly, these mechanisms to overcome immune exclusion and suppression have been shown to complement immune checkpoint therapies in preclinical models. Pepinemab is an IgG4 humanized monoclonal antibody targeting semaphorin 4D. The CLASSICAL-Lung clinical trial tests the combination of pepinemab with avelumab to couple T cell activation via checkpoint inhibition with beneficial modifications of the immune microenvironment via pepinemab. Methods: This phase 1b/2, single arm, first-in-human study is designed to evaluate the safety, tolerability and efficacy of pepinemab with avelumab in 62 patients (pts) with advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC), including immunotherapy-naïve (ION) pts and pts whose tumors progressed following immunotherapy (IOF). Results: Among 21 evaluable ION pts, 5 experienced partial response (PR), 3 pts had clinical benefit ≥ 1 year, and the disease control rate (DCR) is 81%. Pts enrolled in this study were observed to have lower PD-L1 expression relative to prior single agent studies (likely due to approval of pembrolizumab for first line therapy). We, therefore, performed subgroup analysis for response by PD-L1 status. The objective tumor response (ORR) in the PD-L1 negative and low population ( &lt; 80% TPS by Dako 73-10 assay) appears to be approximately 2-2.5 fold greater with combination therapy than with historical single agent immune checkpoint controls. Notably, 97% of pts who experienced PR or SD were reported to have tumors with negative or low PD-L1 expression. Among 29 evaluable IOF pts, the combination resulted in 59% DCR, including 2 PR and 7 patients with durable clinical benefit of ≥ 23 weeks. Biomarker analysis of pre- and on-treatment biopsies confirmed increased CD8 + T cell density correlating with response. Surprisingly, analysis of myeloid-derived suppressor cells (MDSCs) revealed a relative paucity of these cells in pretreatment NSCLC biopsies as compared to other cancer indications such as HNSCC. Conclusions: This trial is nearing completion with only 5 of 62 subjects remaining on study. Preliminary data suggest the combination is well tolerated and shows signs of increased antitumor activity, particularly in PD-L1 negative or low tumors. Updated clinical response data and immunophenotypic analyses will be presented. Clinical trial information: NCT03268057 .
Retrospective analysis of immune checkpoint inhibitor-associated myocarditis from 12 cancer centers in China.
Authors: Feng Wang, Shukui Qin, Fang Lou, Feng Xiao Chen, Meiqi Shi, Xiaohua Liang, Hua Jiang, Yu Jiang, Yu Chen, Yingying Du, Jun Xue, Hong Zhu, Wei Ren
Journal: Journal of Clinical Oncology (2020)

e15130 Background: Immune checkpoint inhibitor(ICI) -associated myocarditis is rare, but it could account for a very high mortality rate. This study reviewed the occurrence of ICI-associated myocarditis in Chinese cancer patients. Methods: A retrospective analysis was made on the occurrence of ICI-associated myocarditis in cancer centers of 12 3A-grade hospitals in China from January 1, 2018 to December 31, 2019. More than 100 patients were treated with ICIs in each center. Results: A total of 2373 patients were treated with ICI alone or in combination. The incidence of ICI-associated myocarditis was 1.05% (25/2373). Of all the data elicited from 16 patients in this study, the tumor types were listed, including: melanoma, lung cancer, renal cancer, urothelial cancer, liver cancer, gastric cancer, colorectal cancer, etc. The 16 patients included 8 male and 8 female with a median age of 65 (36-80). 3 of them had coronary heart disease. The ICI drugs included nivolumab, pembrolizumab and toripalimab, camrelizumab, sintilimab, tislelizumab, atezolizumab. Among them, there were 10 cases of PD-1 inhibitor, 1 case of PD-L1 inhibitor, 5 cases of PD-1 inhibitor combined with chemotherapy or molecular targeted drug. ICI-associated myocarditis occurred in a median of 38 days (2-420) after treatment during which 81.2% (13/16) of them received ICI 1-2 infusions. The common clinical symptoms were palpitation, chest distress and dyspnea, in addition to 8 cases with asthenia, 4 cases with respiratory failure, 2 cases without symptoms. ECG abnormality accounted for 87.5% (14/16). The common abnormalities included: 6 cases of atrial premature contraction, 4 cases of ventricular premature contraction, 3 cases of sinus tachycardia, 1 case of Grade 3 atrioventricular, 1 case of complete right bundle block, and 1 case of acute myocardial infarction. 15 cases of abnormal troponin I or T were observed, followed by CK, CK-MB, MYO and BNP increased. 14 patients were treated with glucocorticoid. 6 patients died with the mortality rate 37.5%(6/16) and 66.7% (4/6) were over 70 years old. Conclusions: The incidence of ICI-associated myocarditis in Chinese patients is low, but the mortality rate is high. Regular monitoring of cardiac biomarkers and ECG is helpful for early diagnosis.